YUHAN CORPORATION Logo

YUHAN CORPORATION

A pharmaceutical & chemical firm developing drugs, supplements, consumer products, and APIs.

000100 | KO

Overview

Corporate Details

ISIN(s):
KR7000100008
LEI:
Country:
South Korea
Address:
서울특별시 동작구 노량진로 74, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Yuhan Corporation, established in 1926, is a leading South Korean pharmaceutical and chemical company. The firm is primarily engaged in the research, development, manufacturing, and sale of a diverse portfolio of products. Its core business segments include Primary & Specialty care, featuring prescription drugs such as the anticancer treatment Lecraza; dietary supplements; household and animal care products; and the contract manufacturing of active pharmaceutical ingredients (APIs). As a pioneering entity in Korea's pharmaceutical sector, Yuhan Corporation is committed to innovation through its advanced R&D capabilities and manufacturing facilities, while also upholding a strong tradition of social responsibility.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.2 KB
2025-09-02 00:00
Transaction in Own Shares
자기주식취득결과보고서
Korean 35.6 KB
2025-08-27 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 7.7 KB
2025-08-27 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 72.8 KB
2025-08-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-08-20 00:00
Regulatory News Service
단일판매ㆍ공급계약체결
Korean 7.7 KB
2025-08-18 00:00
Governance Information
공정거래자율준수프로그램운영현황(안내공시)
Korean 19.7 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 5.3 MB
2025-08-01 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 20.8 KB
2025-07-30 00:00
Earnings Release
영업(잠정)실적(공정공시)
Korean 14.5 KB
2025-07-30 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.6 KB
2025-07-29 00:00
Report Publication Announcement
기업설명회(IR)개최(안내공시)
Korean 6.0 KB
2025-07-01 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득결정)
Korean 34.0 KB
2025-06-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-06-26 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB

Automate Your Workflow. Get a real-time feed of all YUHAN CORPORATION filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for YUHAN CORPORATION

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for YUHAN CORPORATION via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Bioengineering solutions to accelerate life sciences research, from gene synthesis to cell lines.
South Korea
355690
aTYR PHARMA INC Logo
Developing novel medicines for fibrosis and inflammation using tRNA synthetase biology.
United States of America
ATYR
Aura Biosciences, Inc. Logo
Developing virus-like therapies to selectively destroy solid tumors in ocular & urologic oncology.
United States of America
AURA
Aurinia Pharmaceuticals Inc. Logo
Biopharma developing therapies for autoimmune and kidney diseases like lupus nephritis.
United States of America
AUPH
AURORA CANNABIS INC Logo
A global producer and seller of medical and recreational cannabis and derivative products.
United States of America
ACB
Autolus Therapeutics plc Logo
Develops programmed CAR T-cell therapies for cancer and autoimmune diseases.
United States of America
AUTL
AVADEL PHARMACEUTICALS PLC Logo
Develops once-at-bedtime therapies for adults with narcolepsy using innovative drug delivery.
United States of America
AVDL
Avidity Biosciences, Inc. Logo
Pioneering targeted RNA therapies that treat the root cause of rare muscle diseases.
United States of America
RNA
Axsome Therapeutics, Inc. Logo
Biopharma company developing novel therapies for central nervous system (CNS) conditions.
United States of America
AXSM
AYTU BIOPHARMA, INC Logo
Specialty pharma advancing innovative medicines for CNS diseases like MDD and ADHD.
United States of America
AYTU

Talk to a Data Expert

Have a question? We'll get back to you promptly.